- **Revenue Growth**: U.S. net sales up 6% YoY to $51.8 million, driven by 13% QoQ bottle sales growth.
- **Profitability**: GAAP net income $8.8 million (Q3 2025) vs. $5.9 million (Q2 2025); cash burn reduced to $1.6 million.
- **Pipeline Momentum**: ALISCA-Breast1 trial enrolling 98 patients, with interim data expected Q1 2026.
- **Commercial Strength**: 22% YoY call activity growth, 77% dose escalation adoption, and 25% YoY SD channel demand increase.
- **Strategic Focus**: Maintaining profitability while evaluating Phase III potential for alisertib.

**【Management Opening Remarks】**
- Puma reported Q3 2025 total revenue of $54.5 million, including $51.9 million in product revenue (NERLYNX sales) and $2.6 million in royalty revenue.
- U.S. net sales of NERLYNX increased to $51.8 million (Q3 2025) from $48.8 million (Q3 2024), driven by 13% QoQ growth in ex-factory bottle sales to 2,949 units.
- Inventory build of $3.1 million (vs. $1.3 million Q2 2025 drawdown) impacted net revenue growth.
- Full-year 2025 guidance revised to $198-200 million in net product revenue (up from prior range) and $22-23 million in royalties.

**【CEO & CFO Financial Commentary】**
- GAAP net income: $8.8 million (Q3 2025) vs. $5.9 million (Q2 2025); non-GAAP EPS: $0.21 (Q3 2025) vs. $0.12 (Q2 2025).
- Gross to net adjustment increased to 25.9% (Q3 2025) from 20.8% (Q2 2025) due to Medicare rebate costs.
- R&D expenses rose 20-25% YoY due to faster-than-expected enrollment in alisertib trials.
- Cash burn improved to $1.6 million (Q3 2025) from $2.9 million (Q2 2025), with $94 million in cash as of Q3 end.

**【Commercial Performance】**
- Call activity increased 22% YoY and 17% QoQ, with 65% of sales through specialty pharmacies.
- SD channel demand grew 11% QoQ and 25% YoY, driven by 340B purchasing.
- 77% of patients used dose escalation (up from 71% Q2 2025), supporting adherence.
- Total prescriptions declined 1% QoQ but demand increased 3% QoQ.

**【Clinical Pipeline Update】**
- ALISCA-Breast1 trial enrolling ahead of schedule (98 patients, 14 in screening) with interim analysis expected Q1 2026.
- ALISCA-Lung1 trial increased dose to 60mg BID, with 61 patients enrolled (9 at new dose level).
- Company evaluating potential partnerships to diversify pipeline while maintaining profitability.

**【Q&A Highlights】**
- CEO emphasized commitment to remaining profitable while evaluating alisertib's potential Phase III trials.
- 2025 will mark first year-over-year U.S. demand growth for NERLYNX since 2018.
- Company expects to remain debt-free by mid-2026, enabling cash flow for R&D investments.

Puma Biotechnology, Inc. (PBYI) Q3 2025 Earnings Call Transcript

- **Revenue growth**: Q2 2025 product revenue up 14% YoY to $49.2 million, driven by NERLYNX sales growth.
- **Clinical progress**: 62 patients enrolled in breast cancer trial, 52 in lung cancer trial; interim data expected late 2025.
- **Financial strength**: Q2 net income $5.9 million; guiding to $23-28 million for full year 2025.
- **Strategic focus**: Maintain profitability while advancing alisertib trials; no immediate plans to in-license new assets.

**【CEO Summary Section】**
- Q2 2025 total revenue: $52.3 million (product revenue: $49.2 million, up 14% YoY; royalty revenue: $3.2 million, up 11% YoY). 
- NERLYNX sales: 2,608 bottles (Q2 2025), up 12% QoQ and 4% YoY. Inventory decreased by 72 bottles.
- Clinical pipeline updates:
  - ALISCA-Breast1 trial: 62 patients enrolled (targeting HER2-negative, hormone receptor-positive breast cancer), interim data expected late 2025.
  - ALISCA-Lung1 trial: 52 patients enrolled (small cell lung cancer), dose increased to 60mg b.i.d. for better PK, interim data expected late 2025.

**【CFO Financial Commentary】**
- GAAP net income: $5.9 million ($0.12/share) vs. $3 million ($0.06/share) in Q1 2025.
- Non-GAAP net income: $7.5 million ($0.15/share) vs. $6.3 million ($0.13/share) in Q1 2025.
- Full year 2025 guidance:
  - Net NERLYNX revenue: $192-198 million (up 12-15% YoY)
  - Royalty revenue: $20-24 million (down 25% YoY due to China regulatory delays)
  - Net income: $23-28 million
  - Gross to net adjustment: 21.5-22% (up 0.5% YoY)
- Q3 2025 outlook:
  - Net product revenue: $46-48 million
  - Royalty revenue: $2-3 million
  - Net income: $2-4 million

**【Commercial Performance】**
- Call activity up 24% QoQ, 16% YoY.
- SD channel demand growth: 8% QoQ, 17% YoY.
- 71% of patients start on reduced dose (similar to Q1 2025).
- Total prescriptions (TRx) up 3% QoQ, down 2% YoY.

**【Q&A Highlights】**
- ALISCA-Lung1: 40+ patients at 50mg b.i.d. expected for interim data; seeking PFS/OS benefit comparable to prior randomized trial.
- ALISCA-Breast1: 40-45 patients across 3 dose arms expected for interim data; targeting PFS benefit vs. endocrine therapy alone.
- Strategic focus: Maintain profitability (positive net income in Q2 2025) while selectively evaluating in-licensing opportunities.
- No immediate plans to expand R&D beyond alisertib unless trials meet PFS/OS thresholds.


Puma Biotechnology, Inc. (PBYI) Q2 2025 Earnings Call Transcript

- **Revenue trends**: Q1 2025 product revenue down 21% QoQ to $43.1M due to $4.7M inventory drawdown. Full year 2025 guidance: $192-198M net product revenue.
- **Clinical momentum**: 13% ORR in pancreatic cancer with neratinib/Enhertu combo; alisertib Phase II trials enrolling 28 patients vs. 26 expected.
- **Financial health**: Q1 2025 net income $3.0M; 2025 net income guidance $23-28M. Q2 2025 product revenue outlook $48-50M.
- **Strategic focus**: Expanding NERLYNX utilization in high-risk breast cancer patients; exploring new in-licensing opportunities.


**【CEO Summary Section】**
- Q1 2025 total revenue: $46.0 million, with product revenue net of $43.1 million (down 21% QoQ due to inventory decrease) and royalties of $2.9 million (down 38% QoQ). 
- NERLYNX ex-factory bottle sales: 2,338 (down 21% QoQ), with 6% NRx growth QoQ offset by 9% TRx decline.
- Clinical highlights: Phase I neratinib/Enhertu combo trial shows 13% ORR in pancreatic cancer; alisertib Phase II trials enrolling ahead of schedule.

**【CFO Financial Commentary】**
- Q1 2025 GAAP net income: $3.0 million ($0.06/share) vs. $19.3 million ($0.39/share) in Q4 2024 (due to one-time tax benefit). 
- Full year 2025 guidance: Net product revenue $192-198M, royalties $20-24M, net income $23-28M. 
- Q2 2025 outlook: Net product revenue $48-50M, gross to net adjustment 20-21.5%.

**【Q&A Key Highlights】**
- Alisertib manufacturing: Primarily U.S.-based; no immediate tariff impact expected. 
- Lung cancer trial update: Dose increased to 60mg, interim data expected late 2025. 
- Medicare Part D impact: Positive trend with lower patient co-pays, 6% YoY growth in Medicare utilization.


Puma Biotechnology (PBYI)-8 May 25-2025 Q1 Earnings call transcript

- **Q4 2024 Results**: Total revenue $59.1M, with NERLYNX sales growth driven by 9% QoQ bottle sales increase. 
- **2025 Outlook**: Net product revenue $192-198M, net income $23-28M, despite 2% demand decline offset by 7% price hike. 
- **Clinical Momentum**: Phase I Enhertu trial interim data expected at major oncology conferences in H1 2025. 
- **China Risk**: Royalty revenue expected to decline 33% YoY due to regulatory transition. 
- **Cost Control**: 2025 SG&A expenses to decrease 5-10%, R&D up 10-15% for alisertib trials.

**【CEO Opening Remarks】**
- Q4 2024 total revenue: $59.1 million (product revenue: $54.4 million, royalties: $4.7 million). 
- Product revenue decline of $1.7 million QoQ due to $3.7 million inventory build at SPs/Ds, offset by $1.2 million YoY increase. 
- NERLYNX ex-factory sales: 2,964 bottles (+9% QoQ, +3% YoY). 
- New prescriptions (NRx) down 7% QoQ but +10% YoY; total prescriptions (TRx) up 4% QoQ. 
- 2025 Phase I trial with Enhertu expected to present interim data in H1 2025. 

**【CFO Financial Highlights】**
- Q4 GAAP net income: $19.3M ($0.39/share), driven by $7.1M tax benefit. 
- 2025 guidance: 
  - Net product revenue: $192-198M 
  - Royalties: $20-24M (down vs 2024 due to China regulatory transition) 
  - Gross to net adjustment: 20.5-21.5% 
  - Net income: $23-28M 
- Q1 2025 expectations: 
  - Net product revenue: $41-43M 
  - Royalties: $1.5-2.5M 
  - Gross to net: 22.5-23.5% 
  - Net loss: $2M to breakeven. 

**【Commercial Officer Update】**
- 75% of sales via SP channel, 25% via SD channel. 
- BioCare added to SD network for community oncology-focused GPO. 
- 74% of patients start on reduced dose (vs 76% in Q4 2023). 
- NERLYNX launched in extended adjuvant setting in Turkey and Saudi Arabia. 
- 2025 focus: increase engagement with clinicians, improve patient support, optimize persistence/compliance. 

**【Q&A Key Takeaways】**
1. **Enhertu Trial Timing**: Interim data expected at AACR/ASCO in H1 2025. 
2. **China Royalty Volatility**: 2025 shipments expected to decline as Pierre Fabre transitions to direct distribution. 
3. **Payment Reform Impact**: No significant impact on Medicare patients observed so far. 
4. **Alisertib Trial Updates**: 
  - Breast cancer trial enrolling ahead of schedule (14/22 sites activated). 
  - Lung cancer trial protocol expanded to include patients with >2 prior lines of therapy. 
  - Interim data expected late 2025. 
5. **2025 Revenue Mix**: 7% price increase offset by 2% demand decline (forecasted).

Puma Biotechnology (PBYI)-27 Feb 25-2024 Q4 Earnings call transcript

Puma Biotechnology (PBYI)-7 Nov 24-2024 Q3 Earnings call transcript

Puma Biotechnology (PBYI)-1 Aug 24-2024 Q2 Earnings call transcript

Puma Biotechnology (PBYI)-2 May 24-2024 Q1 Earnings call transcript

Puma Biotechnology (PBYI)-29 Feb 24-2023 Q4 Earnings call transcript

Puma Biotechnology (PBYI)-3 Aug 23-2023 Q2 Earnings call transcript

Puma Biotechnology (PBYI)-4 May 23-2023 Q1 Earnings call transcript

Puma Biotechnology (PBYI)-2 Mar 23-2022 Q4 Earnings call transcript

Puma Biotechnology (PBYI)-3 Nov 22-2022 Q3 Earnings call transcript

Puma Biotechnology (PBYI)-7 Aug 22-2022 Q2 Earnings call transcript

Puma Biotechnology (PBYI)-6 May 22-2022 Q1 Earnings call transcript

Puma Biotechnology (PBYI)-4 Mar 22-2021 Q4 Earnings call transcript

Puma Biotechnology (PBYI)-5 Nov 21-2021 Q3 Earnings call transcript

Puma Biotechnology (PBYI)-6 Aug 21-2021 Q2 Earnings call transcript

Puma Biotechnology (PBYI)-7 May 21-2021 Q1 Earnings call transcript

Puma Biotechnology (PBYI)-26 Feb 21-2020 Q4 Earnings call transcript

Puma Biotechnology (PBYI)-5 Nov 20-2020 Q3 Earnings call transcript

Puma Biotechnology (PBYI)-7 Aug 20-2020 Q2 Earnings call transcript

Puma Biotechnology (PBYI)-8 May 20-2020 Q1 Earnings call transcript

Puma Biotechnology (PBYI)-20 Feb 20-2019 Q4 Earnings call transcript

Puma Biotechnology (PBYI)-6 Nov 19-2019 Q3 Earnings call transcript

Puma Biotechnology (PBYI)-8 Aug 19-2019 Q2 Earnings call transcript

Puma Biotechnology (PBYI)-10 May 19-2019 Q1 Earnings call transcript

Puma Biotechnology (PBYI)-28 Feb 19-2018 Q4 Earnings call transcript

Puma Biotechnology (PBYI)-2 Nov 18-2018 Q3 Earnings call transcript

Puma Biotechnology (PBYI)-9 Aug 18-2018 Q2 Earnings call transcript

Puma Biotechnology (PBYI)-9 May 18-2018 Q1 Earnings call transcript

Puma Biotechnology (PBYI)-1 Mar 18-2017 Q4 Earnings call transcript

Puma Biotechnology (PBYI)-9 Nov 17-2017 Q3 Earnings call transcript

PBYI

PBYI fundamentals

Earnings Call

You can ask Aime